Thursday, October 12, 2017 8:25:42 AM
"when it went standard"
Rexista didn't went standard, p3 studies were allowed to be jumped, confirmed by the 25th sept FDA decision. HAP/HAL studies being another story.
The question here (which will remain unresolved) to me is: WHEN (at which stage) Podras was planned to be added to Rexista ? Likely after FDA approval.
But now timeline changed; Rexista is not going to be approved before anytime soon, therefore the point Angelo is making looks interesting to me: chosing to add Podras to an "alternate" oxydone signals the will to advance Podras studies, being the alternative to add-it to a still to approved drug.
Therefore, Always aware that the worst usually happens when Odidi is the decision maker, this time there could be some positive.
JMHO
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM